T1	Participants 95 215	asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer
T2	Participants 424 544	asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer
T3	Participants 782 832	enzalutamide 160 mg/day (n=872) or placebo (n=845)
T4	Participants 3492 3567	chemotherapy-naive men with metastatic castration-resistant prostate cancer
